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Infectious diseases caused by pathogens including viruses, bacteria, fungi, and parasites are ranked as the second leading cause of
death worldwide by the World Health Organization. Despite tremendous improvements in global public health since 1950, a
number of challenges remain to either prevent or eradicate infectious diseases. Many pathogens can cause acute infections that
are eﬀectively cleared by the host immunity, but a subcategory of these pathogens called “intracellular pathogens” can establish
persistent and sometimes lifelong infections. Several of these intracellular pathogens manage to evade the host immune
monitoring and cause disease by replicating inside the host cells. These pathogens have evolved diverse immune escape strategies
and overcome immune responses by residing and multiplying inside host immune cells, primarily macrophages. While these
intracellular pathogens that cause persistent infections are phylogenetically diverse and engage in diverse immune evasion and
persistence strategies, they share common pathogen type-speciﬁc mechanisms during host-pathogen interaction inside host cells.
Likewise, the host immune system is also equipped with a diverse range of eﬀector functions to ﬁght against the establishment of
pathogen persistence and subsequent host damage. This article provides an overview of the immune eﬀector functions used by
the host to counter pathogens and various persistence strategies used by intracellular pathogens to counter host immunity,
which enables their extended period of colonization in the host. The improved understanding of persistent intracellular
pathogen-derived infections will contribute to develop improved disease diagnostics, therapeutics, and prophylactics.
1. Introduction
Infectious diseases caused by bacteria, viruses, fungi, and
parasites can be categorized into extracellular or intracellular
pathogens from an immunopathological perspective. Most
encounters with these pathogenic agents lead to an acute
infection, followed by the development of clinical signs.
These infections are relatively brief, and in a healthy host,
following onset of appropriate immune response, the infec-
tion subsides with elimination of involved pathogens within
days. Acute infections are the typical, expected course for
bacteria like Streptococcus pneumonia and Haemophilus
inﬂuenzae, both commensals of the nasal cavity or viruses
like inﬂuenza virus and rhinovirus. However, some patho-
gens can evade elimination by the host immune system using
various mechanisms and cause persistent infections, which
might lead to lifelong, latent infections. Unlike an acute
infection, a persistent infection is not cleared quickly and
the pathogen, pathogen genome, or pathogen-derived
proteins continue to be produced for long periods; e.g., an
infectious Lymphocytic choriomeningitis virus or Salmonella
Typhi bacteria may be produced continuously or intermit-
tently for months or years [1]. Commensal microorganisms,
which reside at mucosal surfaces, form a protective barrier
that shields the host from microbial invaders [2]. A compro-
mised immune system, an altered microbiota, or breached
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skin or mucosal barriers allow these microorganisms the
opportunity to cause infections. Their ability to persist and
to be transmitted without detection gives such opportunistic
pathogens a unique disease biology that warrants special
attention [3]. Persistent infections can be classiﬁed into
chronic infections, if they are eventually cleared from the
host and latent or slow infections, if they last the life of the
host. In chronic infections, there is a high level of replication
or high burden of the pathogen during the pathogen persis-
tence, e.g., chronic Salmonella Typhi infection. In a latent
infection, an initial acute infection is followed by a dormant
phase and repeated spells of reactivation, which mostly
results in the production of infectious agents but may or
may not be accompanied by symptoms. Examples of latent
viral infections include Herpes Simplex Virus (HSV) and
Epstein-Barr Virus (EBV), while latent bacteria include
Mycobacterium tuberculosis and syphilis causing Treponema
pallidum. In slow infections, a number of years intercede
from the time of initial contact of the infectious agent, mostly
viruses, until the appearance of noticeable symptoms, e.g.,
human immunodeﬁciency virus (HIV) and in rare cases
subacute sclerosing panencephalitis caused by measles virus
[4], which normally is an acute infection. Intracellular path-
ogens can adopt one of these diﬀerent patterns of infection
in the host. Interestingly, many intracellular pathogens thrive
inside one of the most eﬃcient cell types of antimicrobial
defense, namely, mononuclear phagocytes such as macro-
phages and dendritic cells (DCs) [5]. Alternatively, the
endosomal compartment or the cytosol of host cells such as
neutrophils, ﬁbroblasts, or epithelial cells serves as important
habitat for intracellular pathogens [5, 6]. By adopting this
intracellular lifestyle, the pathogens gain access to otherwise
restricted nutrient sources and enjoy rare competition from
other microbes [5]. In addition, their intracellular habitat
protects them from direct attack by antibodies. Once inside
the host cell, a pathogen must replicate without killing the
host cell hastily and without disturbing host cell function
and integrity to ensure its own prolonged survival. Over mil-
lions of years of coevolution with their hosts, pathogens have
evolved various strategies for symbiosis and to evade killing
by the host immune system [7]. These evasion strategies of
microbes have improved our knowledge of infection biology
to a great deal for the development of suitable therapeutics
and vaccines. Furthermore, it has contributed immensely to
understanding of host-pathogen interactions in many persis-
tent infections constituting a great burden of morbidity and
mortality in human diseases.
In this review, we discuss various host-induced immune
mechanisms that are involved in the mediation of protection
against microbial infections, and we address the current
understanding of persistent intracellular infections, includ-
ing mechanisms of their persistence and host-pathogen
interaction.
2. Host Defense against Microbial Infections
Intracellular persistent infections change the nature of the
host, alter immune function and immunological protection,
and predispose the host to other persistent infections [1].
The immune system is an extraordinary diverse compila-
tion of cells that comprise the two arms of the immune sys-
tem, namely, innate and adaptive. Innate and adaptive
immune systems are linked, and innate immune recogni-
tion controls activation of adaptive immune responses [8].
The innate immune system constitutes the ﬁrst line of host
defense against pathogens and recognizes evolutionary con-
served repetitive molecules on pathogens, named pathogen-
associated molecular patterns through germline-encoded
pattern recognition receptors (PRRs) such as Toll-like recep-
tors (TLR), C-type lectin receptors, nucleotide-binding
oligomerization domain- (NOD-) like receptors, and retinoic
acid-inducible gene- (RIG-) I-like receptors [9]. Innate
immune defenses are mediated by complement proteins,
phagocytic cells (monocytes, macrophages, and neutrophils),
and natural killer (NK) cells, and the eﬀector mechanisms of
these cells do not induce immunological memory. Adaptive
immunity is comprised of cell-mediated and humoral
branches and has a broader and ﬁne-tuned repertoire of
recognition due to antigen variability and frequent muta-
tions. The key features of the adaptive immune system are
the immune eﬀector functions, which are pathogen-speciﬁc
owing to receptor rearrangement mechanisms such as
somatic hypermutation (B cell receptor) and V(D) J recombi-
nation (both T and B cell receptor), immunological memory,
and the regulation of host immune homeostasis and toler-
ance. In recent years, the accumulating scientiﬁc evidence
shows that after infection or vaccination, innate immune
cells such as monocytes, macrophages, or NK cells remember
a previous exposure to microbial pathogens or antigens and
undergo long-term functional and epigenetic reprogram-
ming [10, 11]. These changes, described as “trained immu-
nity,” lead to increased responsiveness during secondary
infection, increased production of inﬂammatory mediators,
and increased capacity of protection against infection
through mechanisms independent of T or B cell adaptive
responses. Although the speciﬁcity and the immunological
memory of innate immune cells cannot match with the
highly sophisticated adaptive immune response, the contri-
bution of trained immunity to host defense against infection
should not be underestimated. The concept of trained immu-
nity has potential application for developing improved
vaccines [12, 13] as well as modulation of adverse eﬀects of
inﬂammatory diseases [14]. Figure 1 gives an overview of
key host immune responses against microbial pathogens.
2.1. Cell-Mediated Immunity in Microbial Infections. All
immune responses are driven by T lymphocytes maturing
in the thymus and B lymphocytes maturing in the follicles
of secondary lymphoid tissues such as spleen and lymph
nodes. Both lymphocyte lineages follow almost similar stages
of development and activation; however, there is a remark-
able diversity of eﬀector functions. The various lymphocyte
subsets display a large variation of cell surface signaling
molecules, which are vital for diﬀerentiation, recognition,
and cellular functions [15]. Activation of antigen-speciﬁc T
cells is a complex process and requires the help of antigen-
presenting cells (APCs). Once activated, T cells can diﬀeren-
tiate into distinct subsets and execute their eﬀector functions
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(Table 1). While antibodies (produced by B cells matured
into plasma cells, see Section 2.2) have the possibility to
neutralize extracellular functions of microbial-derived mole-
cules, cell-mediated immunity relies on the various T cells
responding to the presence and presentation of microbial-
derived molecules, typically peptides, and is unable to block
the function of the antigenic molecule.
2.1.1. Intracellular Eﬀector/Killing Mechanisms. Professional
phagocytes, such as macrophages, neutrophils, and dendritic
cells, recognize and internalize microorganisms through
recognition by PRRs or by opsonizing antibodies binding to
Fcγ receptors. This leads to a cascade of signaling events,
remodeling, and focal exocytosis of endomembranes forming
a phagosome. Maturation of the phagosome is characterized
by changes in acidity and acquisition of GTPases, proteases,
and other acid hydrolases and occurs through stages of early
and late phagosome and the highly acidic phagolysosome
formation [114]. Microbicidal activity of the phagolysosome
can be attributed to acidiﬁcation, reactive toxic oxygen
species (ROS), reactive nitrogen intermediates (RNI), antimi-
crobial proteins, and peptides [115]. Antimicrobial proteins
Funji
Protozoa
Bacteria
Bacteria
(extracellular)
Helminth
Virus
Epithelium Positive signal/induction/secretion
Negative regulation/inhibition
Neutrophil
IL-17
Macrophage
Plasma cell
Mast cell Eosinophil Basophil
Figure 1: Schematic representation of the host immune response against microbial pathogens. Microbial pathogens or antigens can be taken
up by the antigen-presenting cells, mostly dendritic cells (DCs), once they breach the epithelial barrier. Antigens are presented to the naive T
cells by the activated DCs through major histocompatibility complex–T cell receptor interaction, which leads to activation and expansion of
antigen-speciﬁc eﬀector T cells (Teﬀ). Teﬀ diﬀerentiate into one of the diﬀerent subtypes, e.g., helper T cells (Th)1, Th2, follicular helper T
cells (Tfh), Th17, or regulatory T cells (Tregs), depending on the cytokine milieu of the microenvironment. Th1 cells activate macrophages or
CD8+ T cells through production of IFN-γ. Activated macrophages fuse their lysosomes more eﬃciently to phagosomes, exposing
intracellular microbes to a variety of microbicidal lysosomal enzymes and toxic oxygen and nitrogen metabolites. Cytotoxic T cells (CTL)
destroy pathogens through release of perforins and granzymes or induce apoptosis of infected cells. Th2 and Tfh cells activate B cells
through production of cytokines and induce the diﬀerentiation of B cells into plasma cells, antibody class switching, and aﬃnity
maturation of antibodies, which remove the pathogen by neutralization, opsonization, and phagocytosis. Th17 cells participate in
neutrophil activation and immune regulation by producing cytokine IL-17A, which is required for protection against extracellular and
some intracellular pathogens. Tregs regulate immune responses to pathogens and maintain self-tolerance by negatively regulating Th1 and
Th2 cells, e.g., by producing cytokines IL-10 and TGF-β. Innate immune cells such as eosinophils, basophils, and mast cells play an
important role in protection against parasitic infections including helminth infections. Natural killer (NK) and natural killer T (NKT)
cells, which form a bridge between innate and adaptive immunity, also contribute to antibacterial and antiviral immunity. NK cells have
similar functions as the CTL while NKT cells produce cytokines to execute their killing functions.
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include secretory granules like lactoferrin, which interfere
with the iron metabolism [116], while a membrane protein,
natural resistance-associated macrophage protein 1, exerts
bacteriostatic eﬀects by extruding Fe2+, Zn2+, and Mn2+ from
the phagosomal lumen [117]. Antimicrobial peptides include
defensins, cathelicidins, lysozymes, lipases, and proteases
Table 1: Lymphocyte subsets in the control of microbial infections.
Lymphocyte
subset
Antigen
presentation
Transcription
factors
Eﬀector molecules
secreted
Mechanism
Evidence for control in
intracellular infections
(gene deﬁciency or direct
involvement)
Th1 MHC class II
T-bet, STAT4,
STAT1
IFN-γ, TNF-α, IL-2,
lymphotoxin α
Activation of macrophages by
IFN-γ, upregulation of iNOS and
ROI, proliferation of CTL
IFN-γ -/- [16–21]
TNF-α -/- [22–29]
IL-12p40 -/- [30–32]
IL-18 -/- [33–35]
Th2 MHC class II
GATA3, STAT5,
STAT6
IL-4, IL-5, IL-9,
IL-13
Stimulate B cells, antibody
production, antibody class
switching
Th2 cytokines [30–32]
Th17 MHC class II RORγt, STAT3
IL-17A, IL-17F,
IL-21, IL-22, CCL20
Recruitment, activation and
migration of neutrophils
IL-17 -/- [36–41]
IL-17 RA -/- [42–47]
IFN-γ -/- [16, 18, 19, 48]
IL-23 -/- [31, 49–51]
Tfh MHC class II Bcl6, c-MAF IL-10, IL-21
Provides help for B cells to allow
formation of plasma cells and
memory B cells
Tfh -/- [52, 53]
IL-21 -/- [54]
IL-6 -/- [55]
Tregs MHC class II
FOXP3, SMAD,
STAT5
IL-10, TGF-β, IL-35
Immunosuppression and
tolerance
CD4+ Tregs [56–58]
CD8+ Tregs [59–61]
IL-10 -/- [57, 62, 63]
TGF-β -/- [64, 65]
CD8+/CTL MHC class I
EOMES,
BLIMP1
IFN-γ, perforin,
granzyme,
granulysin,
FAS-FAS ligand
Cytotoxicity, programmed
cell death by caspase or
receptor-mediated FAS-FAS
ligand apoptosis
IFN-γ -/- [66–71]
TNF-α -/- [22–28, 72]
Perforin -/- [73–75]
Granzyme -/- [75, 76]
γδ T CD1c
PLZF, GATA3,
TBX21
IFN-γ, IL-17A,
IL-17F, IL-22
Pro- and anti-inﬂammatory
functions at epithelial surfaces
γδ TCR -/- [77–82]
IL-17 [37, 38, 46, 83]
IL-22 [84]
NK
MHC class I are
inhibitory
PU.1, Ets-1,
GATA3, IRF-2
IFN-γ, TNF-α,
perforin, granzyme,
α-defensins
Cytotoxic, direct cytolysis by
apoptosis, ADCC
NK -/- [85, 86]
IFN-γ -/- [87, 88]
Perforin -/- [87, 89]
iNKT CD1d
PLZF, TBX21,
ERK
IL-4, IFN-γ,
IL-17A, GM-CSF
Pro- and anti-inﬂammatory
functions
iNKT cells [90–95]
MAIT MR1
ZBTB16,
ROR(γt)
IFN-γ, TNF-α,
IL-17, granzyme
Cytokine production, cytotoxic
MAIT -/- [96–98]
MR -/- [99–101]
B NA
PU.1, Pax5
Ikaros
Immunoglobulins,
IL-10
Antibody secretion,
neutralization, opsonization,
phagocytosis, antigen
presentation
B cells [102–108]
Polymeric-Ig receptor -/-
[109–113]
ADCC: antibody-dependent cellular cytotoxicity; B: B lymphocyte; Bcl6: B cell lymphoma 6; BLIMP1: PR domain zinc ﬁnger protein 1; CCL: chemokine ligand;
CD: cluster of diﬀerentiation; c-MAF: c-musculoaponeurotic ﬁbrosarcoma oncogene homolog; CTL: cytotoxic T lymphocyte; EOMES: Eomesodermin;
ERK: extracellular signal-regulated kinase; Ets-1: erythroblastosis virus transcription factor-1; FOXP3: Forkhead box P3; GATA, trans-acting T cell-
speciﬁc transcription factor; γδ T: gamma delta T cells; GM-CSF: granulocyte-macrophage colony-stimulating factor; IFN-γ: interferon gamma;
Ig: immunoglobulin; IL: interleukin; IL-17RA: interleukin 17 receptor a; iNKT: invariant natural killer T cell; iNOS: inducible nitric oxide synthase;
IRF-2: interferon regulatory factor 2; MHC: major histocompatibility complex; MR1: major histocompatibility complex class I-related gene protein;
MAIT: mucosal-associated invariant T cells; NA: not applicable; NK: natural killer cells; Pax5: paired box protein 5; PLZF: promyelocytic leukemia
zinc ﬁnger; RORγt: RAR-related orphan receptor gamma 2; ROI: reactive oxygen intermediates; STAT: signal transducer and activator of transcription;
TBX: T-box transcription factor; Tfh: follicular helper T cells; TGF-β: transforming growth factor beta; Th: helper T cells; TNF-α: tumor necrosis factor
alpha; Tregs: regulatory T cells; ZBTB16: zinc ﬁnger and BTB domain-containing protein 16.
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[114]. Microbial degradation by lysosomal enzymes may
also lead to generation of antigenic peptides suitable for
presentation by MHC class II molecules and subsequent
CD4+ T cell activation.
2.1.2. Proinﬂammatory Cytokines. IFN-γ is a type II inter-
feron and a key cytokine in intracellular infections that
orchestrates many distinct cellular programs and signaling
events resulting in heightened immune surveillance and
immune function. IFN-γ coordinates a shift from innate to
adaptive immunity through mechanisms such as promoting
development of a Th1-type response by inducing IL-12 and
IL-18 production [118], B cell isotype switching to IgG2a
[119], and regulating leukocyte traﬃcking. IFN-γ also upre-
gulates expression of MHC class I and class II molecules
and promotes induction of cell-mediated immunity and
activation of Th1 cells [120]. Autophagy has been recognized
as a key mechanism by which IFN-γ exerts control over
intracellular pathogens such as M. tuberculosis [121], Toxo-
plasma gondii [122], Chlamydia trachomatis [123], Salmo-
nella [124], and Listeria monocytogenes [125]. The crucial
role of IFN-γ in clearing intracellular infections has been
demonstrated using either antibody-mediated neutralization
assays, IFN-γ receptor α chain, or IFN-γ gene knockout (KO)
mice for infections withM. tuberculosis [16], Chlamydia [17],
Plasmodium [18], Francisella tularensis [19], Leishmania
[20], and Rickettsia spp. [21]. Moreover, IFN-γ therapy was
found to improve the outcome of disease status in tuberculo-
sis patients [126]. In addition to CD4+ Th1 as the principle
source of IFN-γ, CD8+ T cells also contribute to IFN-γ secre-
tion in M. tuberculosis [127], Chlamydia [128], L. monocyto-
genes [129], Rickettsia [21], and F. tularensis [71] infections.
In viral infections, in addition to various eﬀector mecha-
nisms, IFN-γ also induce antiviral enzymes such as protein
kinase dsRNA-regulated (PKR), dsRNA-speciﬁc adenosine
deaminase, and guanylate-binding proteins as well as the
enzymes involved in proapoptotic eﬀects including PKR,
death-associated proteins, FAS/FAS ligand, cathepsin D,
and caspase 1 [120]. Despite the role of IFN-γ in protection
against many intracellular infections, it was shown recently
that protection mediated by CD4+ memory T cells from L.
monocytogenes was mostly dependent on TNF-α, whereas
IFN-γ was found to play only a minor role [130]. Also,
studies with tuberculosis (TB) infection suggest an alterna-
tive mechanism of protection other than IFN-γ [131, 132].
These ﬁndings emphasize that although IFN-γ is important
for protection against various intracellular pathogens, this
cytokine alone is not suﬃcient as a marker of protection
[133]. Besides IFN-γ, TNF-α also activates macrophages
and adopts similar killing strategies against pathogens
including inducible nitric oxide synthase (iNOS), ROS,
RNI, and autophagy. Moreover, TNF-α has a key role in
granuloma formation and containment of disease in TB
[134]. Similar to IFN-γ, studies using KO mouse models
deﬁcient in either TNF-α or p55 TNF-α receptor have
deﬁned a central function for this cytokine in many intracel-
lular bacterial infections such as M. tuberculosis [29], Salmo-
nella [22], Chlamydia [23], Brucella [24], L. monocytogenes
[25], and F. tularensis [26], and in viral infections such as
HSV [27] and HIV [28]. However, in studies on Plasmodium
infection, contradictory results were obtained regarding the
protective role of TNF-α in malaria [135, 136].
Other proinﬂammatory cytokines that are involved in the
defense against intracellular pathogens to various degrees are
interleukin- (IL-) 1α, IL-2, IL-6, IL-8, IL-12, and IL-18. The
cytokines IL-1α, IL-6, and IL-8 play a key role in innate
response and macrophage activation during persistent
intracellular infections such as in Mycobacterium [137],
Chlamydia [138], Leishmania [139], Listeria [140], and
HIV infection [141]. IL-1α also potentiates IL-12-mediated
induction of IFN-γ from NK cells during intracellular infec-
tions. IL-2 production in intracellular infections is associated
with stimulation of cytotoxic T cells and diﬀerentiation as
well as development of T cell immunological memory
[142, 143]. IL-2 is involved in the maturation of regulatory
T cells (Tregs), and IL-2 deprivation is associated with tran-
sient reduction in Tregs, which is essential for optimal T cell
responses and host resistance to microbial pathogens [144].
IL-12 and IL-18 are key cytokines regulating IFN-γ produc-
tion during infection and serve as a bridge connecting innate
and adaptive immunity [145]. IL-18 maturation and release
is promoted by caspase-1, a central mediator of innate immu-
nity that in turn is activated by a multiprotein oligomer,
termed the inﬂammasome [146]. The inﬂammasome is a
molecular complex, which is involved in the activation of
inﬂammatory caspases; promotes the maturation and secre-
tion of proinﬂammatory cytokines, IL-1β, and IL-18; and
activates inﬂammatory responses [147]. IL-12 and IL-18 in
combination further increase IFN-γ levels from macro-
phages, NK cells, and T cells and thus are important cyto-
kines in many persistent intracellular infections [30–35].
2.1.3. Conventional, Regulatory, and Unconventional T Cells.
T lymphocytes that express an αβ TCR as well as a coreceptor
CD4 or CD8, i.e., the so-called conventional T cells recogniz-
ing antigens presented in a peptide-MHC complex, have a
central role in protective and aberrant immunity against
persistent intracellular infections. There are many subsets
of CD4+ T cells, such as T-helper 1 (Th1), Th2, Th17, follic-
ular helper (Tfh), and regulatory T cells (Tregs), and all these
subsets cooperate or interfere with each other to control
infection (Table 1). A CD4+ Th1 cell response is considered
to have a protective role against M. tuberculosis infection
due to production of cytokines such as IFN-γ or TNF-α,
which recruit and activate innate immune cells, like mono-
cytes and granulocytes [16, 29]. Th1 cells also play an impor-
tant role in protective immunity against other persistent
intracellular infections [17–20]. Th17 cells have been found
to be induced following infections with M. tuberculosis [37],
M. bovis [40], Salmonella enterica [83], F. tularensis [41], L.
monocytogenes [50], Leishmaniasis [148], and many viral
infections such as inﬂuenza [43], hepatitis B virus (HBV)
[149], and HIV [150]. The IL-23/Th17 pathway was found
to mediate inﬂammatory responses in intracellular patho-
gens, but was not critical for protection against disease as
IL-17RKO and IL-23KO mice were not found to be more
susceptible to infection with M. tuberculosis [37, 151] or S.
enterica [36] compared to the wild type. However, other
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mouse studies show that absence of the IL-23/Th17 pathway
increases susceptibility to F. tularensis [152], Chlamydia
muridarum [39], and M. bovis bacillus Calmette–Guérin
[38]. Similarly, IL-17RKO and IL-23KO mice have reduced
neutrophil recruiting chemokines such as CXCL-1, -2, -5,
and -8 in the liver and were more susceptible to L. monocyto-
genes infection [50, 153]. In HBV patients, Th17 cell fre-
quency was associated with disease progression and liver
injury [149]. However, increased frequencies of IL-17/IL-22
cells were observed in chronic HBV patients but without
IL-17 correlation with liver ﬁbrosis [154]. Th17 cells have
been found to be involved in the disease progression and
pathogenesis in HIV and Simian immunodeﬁciency virus
infections by inﬂuencing innate immune response and
limiting chronic inﬂammation [150]. Thus, Th17 cells have
diverse roles spanning from cell-mediated direct protective
and indirect helper eﬀects, which are important for intracel-
lular immunity. CD8+ T cells or CTLs remove cells infected
with intracellular pathogens as well as cancerous cells
through contact-dependent lysis and release of cytokines. It
is well-known that CTLs are critical for clearance of many
viral infections, but their exhaustion during chronic viral
infections is accompanied with impaired function and poor
survival [155, 156]. Various studies suggest that IFN-γ pro-
duction by CTLs is required for the clearance of intracellular
bacterial infections such asM. tuberculosis [68], C. trachoma-
tis [69], L. monocytogenes [70], Brucella [67], T. gondii [157],
F. tularensis [158], and Rickettsia [66]. Likewise, perforin
[73–75] and granzyme [75, 76] deﬁciency has been associated
with increased disease pathology in chronic infections with
viruses, bacteria, and parasites.
CD4+FoxP3+CD25+ and CD8+ Tregs play a critical role
in maintaining immunological tolerance to self-antigens
and in suppressing excessive immune responses deleterious
to the host. As an example, CD4+ Tregs were isolated and
correlated with apoptotic activity from human lepromatous
leprosy patients [159]. In addition, patients with active TB
were found to have increased frequencies of CD4+ Tregs
producing IL-10 [56]. In a mouse model of Leishmania
donovani infection, CD4+Foxp3+ Tregs play an important
role in delaying the development of splenic pathology and
restricting leukocyte expansion [57]. In malaria, Tregs
impede host-mediated protective immunity through CTL-
associated protein-4 (CTLA-4) that delays parasite clearance
[58]. Similarly, increased numbers of circulating CD4+ Tregs
have been described in viral infections such as human cyto-
megalovirus (HCMV) and hepatitis C virus (HCV) [160].
In TB [59] and HCV [60], HCMV [161], and EBV [61] infec-
tions, CD8+ Tregs induction inhibits eﬀector T cell responses
and pathogen clearance chieﬂy through TGF-β.
Another category of T cells, the so-called unconventional
T cells, have been identiﬁed in persistent intracellular infec-
tions. These T cells are non-MHC-restricted T cells, which
recognize nonpolymorphic antigen-presenting molecules
and have a more limited TCR repertoire. The unconventional
T cells include γδ T cells, NK cells, NKT cells, invariant
NKT (iNKT) cells, and mucosal-associated invariant T cells
(MAIT) cells. γδ T cells have increasingly been identiﬁed to
play an important role in host defense against persistent
intracellular infections and serves as a bridge between innate
and adaptive immunity [162]. γδ T cell response to infection
is staged and may occur before or after involvement of αβ T
cells. γδ T cells in these immune stages perform diﬀerent
functions due to diﬀerential production of Th1 (early
stage)/Th2 (late stage) cytokines, which has been observed
in infections with inﬂuenza A [163], Schistosoma mansoni
[164], and L. monocytogenes [82]. Additionally, γδ TCR-
deﬁcient mice were found to have 100% mortality following
Nocardia asteroides intranasal challenge due to poor neutro-
philic inﬁltration in the lungs, which could be caused by
decreased IL-17 production [77]. Depletion of IL-17A-
producing γδ T cells resulted in increased bacterial growth
due to poor generation of antigen-speciﬁc CTL responses
[82]. Similarly, increased susceptibility to B. abortus infection
was observed on depletion of γδ T cells in mice compared to
wild types [78]. In advanced stages of L. monocytogenes
infection, depletion of γδ T cells was characterized by liver
necrosis, secondary inﬂammation, and disruption of macro-
phage homeostasis mediated by TNF-α+CD8+ T cells and
reduced IL-10 [79] and IL-17 [82] production by γδ T cells.
Functional loss of γδ T cells as a result of upregulation of
the FAS and FAS ligand has been correlated with disease
progression in M. tuberculosis [80] and HIV-1 infection
[81]. Thus, the role of γδ T cells in persistent intracellular
infections appears to be a regulation of inﬂammation and
subsequent pathogen elimination. NK cells are cytotoxic
lymphocytes and are important connectors between innate
and adaptive immunity via production of cytokines and
interaction with APCs [165]. The role of NK cells has been
documented in the control of tumors and parasitic and early
viral infections. Defects in NK cell activity, such as decreased
production of IFN-γ or cytotoxicity, have been associated
with many viral infections [85, 86]. In the case of HIV infec-
tion, NK cell number and function decrease with disease
progression [166]. A role for NK cells has been identiﬁed in
many protozoal infections including leishmaniasis and
malaria [167]. NK cell-derived IFN-γ diﬀerentially regulates
innate resistance in mice infected with intracellular patho-
gens [87, 88]. Despite the redundant functions of NK cells
in several conditions, NK cells also act as regulatory cells dur-
ing inﬂammation and inﬂuence adaptive immune responses
[165]. NKT cells have an immunoregulatory function pro-
moting cell-mediated immunity to infectious pathogens as
well as tumors. In intracellular infections, iNKT cells are
characterized by release of cytokines such as IFN-γ, TNF-α,
IL-4, IL-5, IL-13, IL-17, chemokines, and rapid eﬀector func-
tions as in Salmonella, Ehrlichia, M. tuberculosis, Trypano-
soma cruzi, and many viral infections [168]. A signiﬁcant
impairment of iNKT cells has been reported in chronic
HIV type 1 infection [90]. In inﬂuenza A virus infection,
IL-22 production by iNKT cells was involved in control of
lung epithelial damage but had no direct eﬀect on viral repli-
cation [91]. In chronic HBV patients, however, restoring the
number of circulating iNKT cells resulted in control of viral
replication accompanied with higher expression of CCR5
and CCR6 [92]. Contrary to these positive eﬀects, iNKT cells
were found to have a detrimental role in the pathology
following experimental dengue virus infection in mice [93].
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Distinct iNKT cell subsets are induced during intracellular
bacterial infections leading to diﬀerential adaptive immune
responses and control of infection as has been observed in
Chlamydophila pneumoniae infection displayed by IFN-γ
production by iNKT cells and by IL-4 production in C. mur-
idarum infection [94]. InM. tuberculosis infection, increased
CD8+ iNKTs were correlated with favorable disease outcome
post-BCG vaccination [95]. A role for MAIT cells in immune
protection against intracellular infections has been demon-
strated, which is consistent with the pathogens sharing
the riboﬂavin pathway and producing riboﬂavin-derived
antigens. In M. tuberculosis infection, MAIT cell levels
are reduced in peripheral blood and lungs of patients with
active pulmonary TB [169]. Similarly, in HCV [170], HBV
[171], and HIV [172] infection, MAIT cells are depleted from
the blood. This depletion was accompanied with expression
of tissue homing markers and detection of MAIT cells in
aﬀected tissues, which suggests that these cells are recruited
to the sites of infection. The depletion of MAIT cells in mice
impedes protection against M. tuberculosis [96], F. tularensis
[98], S. enterica [101], H. pylori [100], Legionella spp. [99],
and inﬂuenza virus [97] elucidating their role in protective
immunity.
Both conventional and unconventional T cells comple-
ment each other during host immune responses against
persistent intracellular infections. While conventional T cells
mostly mediate antigen-speciﬁc functions and immunologi-
cal memory of the cell-mediated immunity, unconventional
T cells have a limited TCR diversity but respond very rapidly
to pathogenic assaults. A full spectrum of cell-mediated
immune responses encompassing conventional, unconven-
tional, and regulatory T cells determines the immunological
outcome in persistent intracellular infections where the
evolution of pathogens has led to diverse escape mechanisms
to establish persistence in the host.
2.2. Humoral Immunity in Microbial Infections. Humoral
immunity is mediated through antibodies produced by B
lymphocytes, which are also APCs, matured into plasma
cells. B cells and antibodies contribute signiﬁcantly to shape
the immune response to and/or induce protection against
many persistent intracellular pathogens [104, 105, 173] with
the important distinction from cell-mediated immunity, that
antibodies may functionally block the antigenic target. B cells
undergo class switching and aﬃnity maturation in the
germinal centers to form antibodies of isotypes such as IgG,
IgA, and IgE, which mediate their protective eﬀects via
neutralization, opsonization, and complement activation.
Neutralization by antibodies is an important classical eﬀector
mechanism against viruses [174] and is a key correlate of
protection for many infections [175]. Recently identiﬁed
nonclassical antibody functions include direct antimicrobial
activity, alteration of signaling by engaging FCR, immuno-
modulation, and modulation of microbial physiology [176].
Previously, it was believed that immunoglobulins could not
enter infected cells and thus do not participate in combating
intracellular bacterial infections. However, in L. monocyto-
genes infection, the anti-listeriolysin O antibody neutralizes
listeriolysin toxin and protects the host from infection
[177]. A comparison between the antibody proﬁles of latently
versus actively M. tuberculosis infected individuals also
points to a functional role of antibodies in the control of
TB [106], and naturally occurring IgM from B1 cells have
been reported to induce innate disease resistance against
intracellular infection with inﬂuenza virus in mouse models
[178]. In addition to the antigen speciﬁcity of antibodies, the
diﬀerent Fc variations may also have both pro- and anti-
inﬂammatory functions and enhance microbial clearance
through complement activation or idiotype-anti-idiotype
interactions [176]. The cellular basis for these properties of
antibodies is associated with ligation to stimulatory and
inhibitory FCRs [179]. In line with this, FCRs were shown
to be key elements in protective responses against intracellu-
lar pathogens chieﬂy through oxidative burst, antibody-
dependent cellular cytotoxicity, and induction of T cell
responses by cytokines for infections with M. tuberculosis
[106], C. trachomatis [102], S. typhimurium [180], F. tularen-
sis [107], Leishmania major [103], Legionella pneumophila
[104], L. monocytogenes [108], and T. gondii [105]. A
complete T cell independent humoral immune response
mediated by B cells and antibodies was even demonstrated
in Ehrlichia muris infection [173]. In addition, low secreted
IgA (sIgA) was associated with disease pathology in
polymeric-Ig receptor-deﬁcient mice [109–113], highlighting
the role of sIgA in protection against persistent pathogens. In
chronic intracellular infections, the same antibody may be
proinﬂammatory or anti-inﬂammatory depending on the
host and the stage of infection; e.g., during Cryptococcus neo-
formans infection, administration of IgG1 before or after the
onset of infection can result in anti- or proinﬂammatory
eﬀect, respectively [176]. It thus appears that the protection
mediated by antibodies cannot be deﬁned solely by molecular
structure and glycosylation of antibodies but also depends on
components of host as well as the pathogen and the stage of
infection [176].
3. Mechanisms of Microbial Persistence
One characteristic of intracellular pathogens is their ability to
maintain infection in the host even in the presence of innate
and adaptive immune responses [181]. In some cases, persis-
tent intracellular infections are asymptomatic, although the
infection can pose a risk to the host, especially if the disease
is reactivated from an innocuous state of dormancy.
Persistent infections can be divided into two groups. One
includes those pathogens, which are kept in check by
adaptive immune responses in a state of dormancy but are
not completely removed from the host, such asM. tuberculo-
sis [16, 182, 183] and S. enterica [184]. The second group
includes opportunistic pathogens that reside among com-
mensal ﬂora in the mucosa without inducing adaptive
immune responses in healthy hosts, but are capable of estab-
lishing active and threatening infection in immunocompro-
mised hosts, such as Neisseria [185]. Thus, there is always
an intimate crosstalk between the host and the pathogen,
and the pathogens have evolved numerous anti-immune
strategies for continuous lifelong survival to escape host
immune elimination by overcoming both innate and
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adaptive immunity [181]. This balance of host immune
response and pathogen counter-defense contributes to the
complexity of persistent infections. Figure 2 summarizes
the mechanisms of persistence of selected intracellular
pathogens.
Despite the diversity, there are several general mecha-
nisms for subversion of host immune responses that are
shared between microbial pathogens. These can be divided
into two broad groups: (a) evasion of host immune recogni-
tion such as modulation of microbial surfaces, secretion of
immunomodulators, antigenic variation, and hiding in safe
target cells or tissues (Table 2) and (b) modulation and
suppression of host immune responses such as evasion of
phagocytosis, innate immune receptors, complement system,
cytokines, or chemokines; inhibition of apoptosis; resis-
tance to host eﬀector mechanisms; and induction of inap-
propriate immune responses such as immunosuppression
and induction of Tregs (Table 3). Strategies adopted by per-
sistent microbial pathogens is a broad topic, and reviewing
it comprehensively is more suitable for a full book, so we have
chosen to highlight some key mechanisms, which the patho-
gens use to ensure their prolonged survival.
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Figure 2: Schematic representation of the mechanisms of persistence of selected intracellular pathogens. Left: an overview of the various
mechanisms used by pathogens to overcome innate and adaptive immune responses. The major strategies are discussed in more detail in
the text. Right: evasion strategies of various phagocytic mechanisms by selected intracellular pathogens. Viruses such as inﬂuenza virus are
able to inhibit the activation of antiviral mechanisms, such as the production of interferon upon viral infection, and enter the nucleus.
Mycobacterium tuberculosis after phagocytosis acquires the early endosome marker Rab5, which blocks fusion with the lysosome, and the
mycobacteria replicate in this early endosome. Legionella pneumophila resides and multiplies in vacuoles that acquire Rab1 and secretes
eﬀector molecules via its type IV secretion system, which inhibits phagolysosome formation. Listeria monocytogenes-engulfed phagosome
undergoes acidiﬁcation, which perforates the phagosomal membrane and the bacteria escape into the cytosol, where they move within and
then among cells with actin polymerization. Chlamydia spp. are present as nonreplicating infectious “elementary body” and
intracytoplasmic replicating noninfectious “reticulate body.” The elementary body induces its own endocytosis upon exposure to host cells
and survives and multiplies inside phagolysosome before infecting the new host. Coxiella burnetii and Brucella abortus are present inside a
vacuole, which becomes acidic and acquires Rab5 followed by Rab7 that prevents phagolysosome formation. The Francisella tularensis
phagosome acquires Rab5 (early endosome) and then Rab7 (late endosome). Late endosome is not acidiﬁed, which disrupts the
phagosomal membrane discharging the bacteria into the cytosol. These vacuoles fuse with the endoplasmic reticulum, which allow
bacterial replication. Leishmania spp. phagosome becomes acidic phagolysosome, which bears Rab7, and the parasite survives and
multiplies inside the phagolysosome.
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3.1. Evasion of Host Immune Recognition
3.1.1. Surface Immunomodulation. The external surface of
microbial pathogens is the ﬁrst interface of pathogen and
host interactions. This interface provides numerous opportu-
nities for both pathogen and host to modulate and shift the
immune equilibrium in their favor. Pathogens avoid immune
detection by secreting immunomodulators from infected
cells, including proteins and toxins [233, 234], and express
receptors and inhibitors, modifying their own surface
molecules/ligands [235]. Some viruses have evolved viral
cell-surface proteins that mimic the structure as well as
function of host cell receptors; e.g., herpes and poxviruses
encode over 40 viral proteins that hijack transmembrane
G-protein coupled-receptor signaling networks of the host
[189, 190]. Bacterial pathogens have evolved ways to alter
the TLR agonists on their surfaces such as lipid A, ﬂagella,
and peptidoglycan [236]. Many bacterial pathogens modify
lipid A to avoid TLR4 detection and include Salmonella
[186], Neisseria [237], and Yersinia [238]. In addition,
some bacterial pathogens have evolved methods to avoid
processing of peptidoglycan-derived muropeptides and
their detection by the cytosolic receptors, NOD1 and
NOD2 proteins [187]. Peptidoglycan plays an important
role in the pathogenesis of many persistent intracellular
infections [188].
3.1.2. Secretion of Immunomodulators. Persistent bacterial
pathogens have developed a secretion system to deliver
virulence factors such as toxins and eﬀectors interfering
with apoptosis into the host cell, thereby enhancing intra-
cellular survival. Out of seven such secretion systems,
type III (T3SS) (used by Chlamydia trachomatis and
Salmonella typhimurium) and type IV secretion systems
(T4SS) (used by Legionella and Brucella) are the most
widely studied [192, 193, 239]. M. tuberculosis uses a spe-
cialized secretion system, Esx secretion systems (ESX-1,
ESX-3, and ESX-5), to deliver major T cell antigens
ESAT-6 and CFP-10 into the host [191]. Similarly, secre-
tion systems have been described for gram-positive bacte-
ria, e.g., Ess system of Staphylococcus aureus [194] and
the Yuk/Yue system of Bacillus subtilis [195]. Ess plays
a key role in virulence of S. aureus allowing it to persist,
establish staphylococcal abscesses, and evade the host
immune response [194]. The Yuk/Yue system of Bacillus
subtilis mediates YukE protein secretion and is homolo-
gous to Ess proteins of S. aureus [195]. In the case of
viruses, secreted viral immunomodulators mimic a wide
range of host molecules including cytokines, chemokines,
interferons, and complement and inﬂammatory cascades
[240, 241]. These secreted viral immunomodulatory pro-
teins are excellent targets for developing novel immunother-
apeutic strategies [242].
Table 2: Selected mechanisms for evasion of host defense by persistent intracellular pathogens.
Mechanism Pathogen(s)
Pathogen
type
Remarks Reference(s)
Immunomodulation
Salmonella spp. B Lipid A modiﬁcation [186]
Leptospira interrogans B Peptidoglycan modiﬁcation [187, 188]
Poxvirus V Host cytokine decoy receptors [189]
Herpesvirus V Host cytokine and chemokine decoy receptors [190]
Mycobacterium tuberculosis B ESX secretion system [191]
Salmonella typhimurium B Type III secretion system [192]
Brucella abortus B Type IV secretion system [193]
Staphylococcus aureus B Ess secretion system [194]
Bacillus subtilis B Yuk/Yue secretion system [195]
Antigenic variation
Inﬂuenza virus V Antigenic drift/shift [196]
Neisseria spp. B DNA rearrangement [197, 198]
Plasmodium spp. P Programmed gene rearrangement [199]
S. Typhimurium B DNA rearrangement [200]
Trypanosoma brucei P Programmed gene rearrangement [201]
Hepatitis C virus V DNA rearrangement [202]
Human immunodeﬁciency virus V DNA rearrangement [203]
Hiding in safe target
cells/tissues
Epstein-Barr virus V B cells [204]
Herpes simplex virus V Sensory neurons [27, 205]
Leishmania spp. P Fibroblasts [206]
Mycobacterium leprae B Peripheral nerves (Schwann cells) [207]
Salmonella enterica Typhi B Reticuloendothelial system [208]
Toxoplasma spp. P Cerebellar neurons [209]
Varicella zoster virus V Dorsal root ganglia [210]
B: bacteria; P: protozoa; V: virus.
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3.1.3. Antigen Variation. Antigenic variation is another
classical method adopted by persistent pathogens to
avoid immune responses especially the adaptive immune
responses. Among bacterial pathogens, Neisseria is one of
the best examples for antigenic variation. The pathogenic
Neisseria have three antigenically or phase-variable major
surface determinants: the opacity (Opa) outer membrane
proteins, which govern bacterial adhesion and uptake into
host cells; lipooligosaccharide (LOS), which is present in
the outer membrane and is involved in host interactions;
and type IV pilus (Tfp), which is involved in cellular
adherence [197]. There are up to 11 antigenically diﬀerent
Opa proteins and 12 recognized LOS immunotypes that
are turned on and oﬀ independently and exhibit multiple
combinations [198]. Tfp antigenic variation relies on a
programmed homologous recombination system to express
antigenically distinct peptide sequences [197]. Variant sur-
face glycoprotein (VSG), the major surface component of
the protozoan parasite Trypanosoma brucei, is another
example of antigenic variation. VSG exists in the blood
and tissues of its mammalian host, but during an infec-
tion, some T. brucei parasites will switch their VSG to a
Table 3: Selected mechanisms for modulation/suppression of host immune response by persistent intracellular pathogens.
Mechanism Pathogen(s)
Pathogen
type
Remarks Reference(s)
Subversion of host defense
Brucella spp. B
Inhibit fusion with host lysosomal
compartment and alter lysosomal pH
[211]
Chlamydiae spp. B
Degradation of host proteins and
deactivation of neutrophils by
chlamydial protease-like activating
factor
[212, 213]
Francisella tularensis B Escape into cytosol [214]
Anaplasma phagocytophilum B
Inhibits autophagosomal-lysosomal
fusion
[215]
Legionella pneumophila B
Membrane-bound vacuole and eﬀector
protein (Ank protein) release
[216]
Listeria monocytogenes B Escape into cytosol [217]
Mycobacterium tuberculosis B Inhibition of phagolysosome formation [183]
Rickettsia spp. B
Escape into cytosol and replicate in
cytoplasm of host cell
[218]
Salmonella enterica Typhi B
Inhibit fusion with host lysosomal
compartment and alter lysosomal pH
[36, 219, 220]
Toxoplasma gondii B Generate own vesicle [221]
Resistance to host eﬀector
mechanisms
Cytomegalovirus V
Inhibition of humoral immunity and
inﬂammatory response. Blockage of Ag
processing and presentation
[63]
Epstein-Barr virus V Inhibition of inﬂammatory response [204, 222]
Herpes simplex virus V
Inhibition of humoral immunity and
blockage of Ag processing and
presentation
[27, 205]
Leishmania spp. P Silent phagocytosis [206]
Mycobacterium tuberculosis B Ability to persist in macrophages [183]
Vaccinia virus V
Inhibition of humoral immunity and
inﬂammatory response
[223–225]
Induction of inappropriate immune
responses/immunosuppression/Tregs
Hepatitis C virus (HCV) B
Immunosuppression by complement
regulatory pathway
[160, 226–228]
Mycobacterium leprae B
Immunosuppression of Th2 cytokines,
indoleamine 2, 3-dioxygenase
[159, 229]
HCV V Induction of Tregs [160, 227]
Human immunodeﬁciency
virus
V Induction of Tregs [161]
Leishmania major P Induction of Tregs [103, 230]
M. Tuberculosis B Induction of Tregs [231]
Plasmodium spp. P Induction of Tregs [232]
Ag: antigen; B: bacteria; P: protozoa; Th2: type 2 helper T cells; Tregs: regulatory T cells; V: virus.
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new and antigenically distinct variant, which results in a
typical parasitemia in the infected host [201]. Similarly,
RNA viruses use antigenic variation for evading host
immune responses through the mechanisms of antigenic
drift and shift as seen with HCV [202], HIV [203], and
inﬂuenza virus [196]. DNA viruses, both single, e.g., par-
vovirus [243], and double-stranded, e.g., cytomegalovirus
[244], exhibit mutations to permit selective escape from the
host immunity.
3.1.4. Subversion of Host Defense and Hiding. Successful
pathogens thwart all or most host immune defenses to
remodel their intracellular habitat into a safe compartment.
Once inside professional phagocytes, pathogens can still
reach a stage of persistence if they manage to counter antimi-
crobial eﬀector mechanisms, escape the phagolysosome, or
modify their intracellular habitat into a safe niche [245];
e.g., Yersinia pestis uses its T3SS to inject Yersinia outer pro-
teins that counter multiple signaling responses initiated by
phagocytic receptors [246]. Other bacterial pathogens avoid
killing after phagocytosis by three strategies: (i) escape from
phagosome, (ii) prevention of phagosome-lysosome fusion,
and (iii) survival inside the phagolysosome. The ﬁrst evasion
strategy is adopted by Listeria [217, 247, 248] and Rickettsia
spp. [218]. L. monocytogenes is considered as the phagosomal
escape artist as it uses a sophisticated eﬀector mechanism
through listeriolysin, phospholipases, and an eﬀector protein
ActA, which causes breakdown of the phagosome and escape
of bacteria into the cytosol [217, 247, 248]. M. tuberculosis
and Salmonella use the second strategy for persistence.
Salmonella uses its T3SS called Spi/Ssa that exports the
SPI-2 pathogenicity island-encoded SpiC protein into the
host cell cytoplasm and eﬃciently blocks phagosome-
lysosome fusion [249]. In comparison, M. tuberculosis uses
a combined strategy by employing a range of protein and
lipid eﬀectors such as SapM, ZmpA, kinases, and lipoarabi-
nomannan, which deplete phosphatidylinositol 3-phosphate
from early phagosomes and prevent phagolysosome forma-
tion [250]. In addition, mycobacteria use ESX secretion
system to prevent phagolysosomal fusion [191]. Finally,
pathogens such as Salmonella, Leishmania, Staphylococci,
and Coxiella can survive and even replicate inside the acidic
and hydrolytic environment of the phagolysosome. Salmo-
nella uses the PhoP/PhoQ regulatory system for survival
[251], while Leishmania, Coxiella, and Francisella in addition
to replication can draw nutrients at an acidic pH of the
phagolysosome [252–254]. Staphylococcus aureus employs
mechanisms such as perturbation of macrophage phagoly-
sosome formation [255] and inhibition of neutrophil
myeloperoxidase [256]. Viruses usually subvert lysis by
phagocytic cells by preventing iNOS induction, which is
under the control of NF-κB and STAT-1 [257]. A range of
virus-encoded proteins have been identiﬁed that inhibit
NF-κB activation or kinases [257]. However, some viruses
maintain a balance between NF-κB activation and suppres-
sion to maintain a state of latency, e.g., HSV [205]. Bacterial
pathogens, on the other hand, use proteins of secretion sys-
tems to modulate NF-κB signaling, e.g., T3SS protein YopJ
in Yersinia [258], AvrA in S. enterica [219], SseL in S.
typhimurium [259], and T6SS eﬀectors and a heat shock pro-
tein ClpB in Francisella tularensis [214]. Other bacterial
eﬀector proteins, which have been identiﬁed, are CP0236
in C. pneumoniae [260], ChlaDub1 in C. trachomatis [208],
LegK1 in Legionella pneumophila [216], and IKK in Toxo-
plasma gondii [221].
3.2. Modulation or Suppression of Host Immune Responses
3.2.1. Subversion of Innate Immune Receptors. One of the
mechanisms for subversion of host defense by pathogens is
the evasion of PRR signaling. Viruses have evolved several
mechanisms to avoid detection by PRRs or to inhibit the
activation of PRRs and/or their downstream signaling cas-
cades. Earlier evidence came from studies where some viruses
encoded proteins to target TLR signaling, such as pox viruses
through protein A52R [261] and hepatitis viruses through
TRIF protein [262]. Since then, various TLRs have been
shown to be involved in responses to viral infections includ-
ing TLR1, -2, -3, -4, -6, -7, -8, and -9 [263]. Many RNA
viruses replicate in the cytoplasm and are detected by the
cytoplasmic PRRs, MDA5, and RIG-I, which are targets for
viral evasion. RNA viruses such as ﬂaviviruses, which include
dengue virus and HCV, induce membrane modiﬁcations,
which prevent their recognition by RIG-I and MDA5 and
result in poor induction of type I IFN [264, 265], while
enteroviruses including poliovirus cleave RIG-I and MDA5
by proteases, 2Apro and 3Cpro, are required for viral polypro-
tein processing [266]. Inﬂuenza virus targets host TRIM25
and RIPLET proteins, which are required for the full activa-
tion of RIG-I [267]. DNA viruses replicate within the nucleus
and are detected in the nucleus or in the cytoplasm by IFI16
or cGAS, respectively. In response, DNA viruses have
evolved various strategies to evade these receptors; e.g.,
HSV-1 produces a protein, ICPo, that ubiquitinates IFI16
and results in its degradation by the ubiquitin proteasome
and eventually loss of IFN induction [268]. In HIV-1 infec-
tion, the viral cDNA is protected within the viral capsid,
which prevents its exposure to cGAS in the cytoplasm
[269]. In addition to above, viruses also use other strategies
such as targeting adaptor proteins and their kinases during
downstream signaling of antiviral innate immune pathways,
inhibiting transcription factors involved in IFN induction,
and evading IFN-stimulated genes [270]. Among bacterial
pathogens, there are only a few, which directly inhibit the
PRR signaling. Yersinia pestis is a typical example, where
the virulence antigen, LcrV, speciﬁcally hijacks the TLR2/6
pathway to stimulate IL-10 production, which blocks host
protective inﬂammatory responses [271]. Some bacterial
pathogens target intracellular signal transduction pathways
such as the mitogen-activated protein kinase (MAPK) signal-
ing axis, TGF-β-activated kinase 1 (TAK1), and the NF-κB
pathway. The eﬀector protein YopJ of Y. pestis targets several
MAPK and TAK1 [272]. Similarly, Salmonella eﬀector pro-
tein AvrA mediates bacterial intracellular survival during
infection by inhibiting MAPK4 and MAPK7 [273]. Bacteria
also subvert host immune responses by directly interacting
with inhibitory receptors such as the immunoreceptor
tyrosine-based inhibitory motif- (ITIM-) bearing inhibitory
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receptor or through virulence factors that mimic intermedi-
ates of host inhibitory signaling [274]. For instance, S. aureus
targets the ITIM-bearing inhibitory receptor paired Ig-like
receptor B (PIR-B) to reduce TLR-induced inﬂammatory
cytokine release by macrophages during infection [275].
Helicobacter pylori releases eﬀector proteins, which contain
ITIM-like motifs within host cells and suppress immune
responses [276]. On the other hand, Yersinia and Salmonella
impair inﬂammatory signaling by secreting eﬀectors that
resemble host cellular protein tyrosine phosphatases [274].
The blockade of these inhibitory receptors may be a novel
strategy to improve the host-mediated immunity against
persistent pathogens.
3.2.2. Evasion of Autophagy. Autophagy is a process that
engulfs and delivers cytoplasmic constituents for lysosomal
degradation and is a target for maintaining persistence by
intracellular pathogens. L. monocytogenes evades autophagic
recognition by proteins ActA and internalin K [247] while
L. pneumophila eﬀector protein RavZ inhibits autophagy
through irreversible Atg8 protein deconjugation attached
on autophagosome membranes [277]. Some intracellular
bacterial pathogens, e.g., Anaplasma phagocytophilum, lives
within an autophagosome and inhibits autophagosomal-
lysosomal fusion by secreting protein Anaplasma translo-
cated substrate 1 that hijacks the Beclin 1-Atg14L autophagy
initiation pathway [215]. Viruses are very adept in evading
autophagy early during autophagosome formation and
during autophagosomal-lysosomal fusion. For example,
TRIM proteins were found to regulate autophagy by HSV-1
and inﬂuenza A virus via the TRIM23-TBK1-p62 axis as a
key component of selective autophagy [278]. Picornaviruses
including poliovirus and food-and-mouth disease virus
subvert autophagy and generate unique replication organ-
elles for their multiplication [279]. Similarly, HCV triggers
Golgi fragmentation and autophagy through the immunity-
related GTPase M [280]. Evasion of autophagy is also used
by RNA viruses that replicate in the nucleus, e.g., HIV, which
inhibits autophagosome maturation via Tat, Nef, and Vpu
proteins [281].
3.2.3. Inhibition of Complement Proteins. The complement
system is another target for persistent pathogens aiming
at evading the host innate immune response. Viruses like
HCMV, HIV, and human lymphoma virus type I incorpo-
rate complement inhibitor proteins DAF, MCP, and CD59
in their envelope during virus release from the cell [282]
while others like poxvirus and the herpesviruses encode
homologues of complement inhibitors. A number of bacte-
ria express surface proteins that can bind C4BP (classical/
lectin pathway) or factor H (alternative pathway) and
thereby prevent their cofactor functions in factor I-
mediated cleavage of C3b/C4b and subsequent complement
activation [283]. Among persistent bacterial pathogens,
Neisseria is a classical example for evading complement
activation. N. gonorrhea expresses two kinds of porin mol-
ecules, Por1A and Por1B, that binds complement compo-
nent C4BP [284].
3.2.4. Inhibition of Cytokines and Chemokines. Inhibiting the
production of cytokines, such as type I and II interferons,
TNFs, and IL-1, and chemokines is another way to escape
host immune responses, and such strategies have been very
well documented for viral infections [285]. In addition, large
DNA viruses (herpes and poxviruses) are able to express
surface proteins that mimic cytokine and cytokine receptors
[286]. Other viruses modulate the chemokine network by
producing their own versions of chemokines or chemokine
receptors or by secreting chemokine-binding proteins, not
found in the host [286]. Persistent bacterial pathogens can
manipulate the cytokine network by producing eﬀector
proteins, which inhibit cytokine release such as TNF-α
release in Yersinia enterocolitica [287] and Brucella suis
[288] and IL-2 in S. typhimurium [289], while Legionella
pneumophila degrades IL-2 by producing a Zn metallopro-
teinase [290].
3.2.5. Inhibition of Adaptive Immune Responses. Adaptive
immune responses are critical for the clearance of bacterial
and viral infections. However, persistent pathogens have
acquired various mechanisms to counteract the adaptive
immune response at various levels. In viral infections, NK
cells are part of the ﬁrst line of cellular defense, which can
be countered through expression of viral proteins blocking
either NK-cell receptor function, cytokine release, or
MHC-I homologs [291]. HBV suppresses NK cell function
by upregulating the inhibitory molecule, T cell immunoglob-
ulin, and mucin protein-3 (Tim-3) on NK cells [292] while
HCV inhibits NK cell activity by crosslinking CD81 with its
viral glycoprotein E2 [293]. Viral interference with protea-
some cleavage, translocation through the transporters associ-
ated with antigen processing, and presentation through
MHC class I as well as MHC class II have been documented
for persistent infections with HIV, HSV, HPV, HCMV, and
adenovirus [285]. Viruses can interfere with DC functions
in many ways and modulate their eﬀector functions [294].
Viruses also evade neutralizing antibodies; e.g., cell-to-cell
spread of HCV prevents antibody-virion contact [295], and
mutations in glycoproteins of both HCV [296] and HPV
[297] reduce host antibody reactivity. Among bacterial path-
ogens, N. gonorrhea manipulates host immune responses by
inhibition of T lymphocyte activation and proliferation
(mediated by the Opa protein) [298]. A vacuolating immu-
notoxin, VacA, produced by H. pylori, inhibits proliferation
of T lymphocytes via the TCR-IL-2 signaling pathway
[299]. Other bacterial pathogens reduce MHC antigen
presentation and evade host T cell response; e.g.,M. tubercu-
losis-infected cells export antigen for uptake and presentation
by uninfected bystander cells, which reduce MHC class II
antigen presentation by infected cells and limits host-
mediated CD4+ T cell control [300]. B. abortus infection
inhibits the expression of MHC-II molecules by IL-6-
dependent inhibition of transactivator (CIITA), which
prevents its recognition by T cells establishing a chronic
infection [301]. Another evasion strategy adopted by bacte-
rial pathogens is to secrete enzymes such as IgA proteases
that degrade immunoglobulins; e.g., secreted IgA protease
from N. meningitidis is transported to the nucleus of infected
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cells where it cleaves the p65/RelA component of the NF-κB
complex [302]. Immune checkpoint inhibitors, e.g., CTLA-4,
programmed death- (PD-) 1, lymphocyte-activation gene 3
(LAG-3), and Tim-3, are today well recognized in the
immune evasion of cancers [303]. Microbial pathogens can
also exploit immune checkpoint inhibitors to limit host-
mediated antigen-speciﬁc immune responses; e.g., S. aureus
modulates PD-ligand 1 to evade immune activation [304].
In Plasmodium falciparum infection, Tim-3 on immune cells
negatively regulates cell-mediated immunity, the blockade of
which improves protection against malaria [305]. Similarly,
Tim-3 mediates T cell exhaustion during M. tuberculosis
infection [306]. PD-1 has been implicated in the regulation
of T cell responses during HIV, HCV, and HBV infection
[307]. Immune checkpoint blockade may be an important
novel strategy for managing chronic infections, which
presently lack eﬀective therapies or vaccines [307].
3.2.6. Suppression of Cell Death. Induction of cell death is one
of the canonical strategies used by phagocytes to clear
intracellular pathogens by expelling microbes from their rep-
licative niche. Successful intracellular pathogens modulate
diﬀerent forms of cell death such as apoptosis, pyroptosis,
necrosis/necroptosis, and NETosis, to evade host immune
defense [308]. Apoptosis is an active programmed cell death,
which does not induce inﬂammation but is dependent on
sequential proteolytic activation of caspases. Cellular pro-
teins involved in the control of apoptosis, such as FLIP,
caspase inhibitor, selenoproteins, ligands of the TNF family,
Bcl-2, and p53, are targeted by viral antiapoptotic mecha-
nisms such as inhibition of multiple caspases and TNF-
induced apoptosis, inactivation of p53, and homologs of
Bcl-2 [285]. A number of virus-encoded proteins interfere
with caspase activation or inhibit caspase activity and avoid
apoptosis of host cells for their survival; e.g., the HSV-1
latency-associated transcript blocks apoptosis and inhibits
caspase-3 activation [309]. Bacterial infections may drive
the antiapoptotic pathways through production of bacterial
toxins as in Listeria infection or secretion of eﬀector proteins
and T3SS as in Salmonella and Yersinia infections [310, 311]
or by blocking proapoptotic proteins Bax and Bak or activate
caspase-3 as in Chlamydia infection [312]. However, recently
it was reported that although C. trachomatis-infected cells are
protected from apoptosis at early and mid-stages of infection,
they remain susceptible to the induction of other cell death
modalities, especially necrosis [313]. It was also shown that
this necrotic death occurred with similar kinetics as apoptosis
in uninfected cells, which indicates that C. trachomatis fails
to signiﬁcantly prolong the lifespan of its host cell when
exposed to proapoptotic insults [313]. Rickettsia rickettsii
inhibits apoptosis through induction of NF-κB-mediated
events, and as a result, the infected host cell remains at the
site of infection [314]. Coxiella burnetii eﬀector protein CaeA
interferes with the intrinsic and extrinsic apoptosis pathway
[315]. Necrosis is a caspase-independent pathological cell
death, which triggers inﬂammation and results in extensive
tissue damage [308]. M. tuberculosis infects macrophages
and induces necrosis to avoid immune response and to dis-
seminate [316]. Necroptosis is a form of regulated necrosis
that depends on activation of the necrosome, which is a
protein complex in which receptor-interacting protein kinase
3 (RIPK3) is activated. Vaccinia, inﬂuenza, and HSV-1 are
among many viruses that induce necroptosis via their eﬀec-
tor proteins binding to RIPK3 [317]. Pyroptosis is a highly
inﬂammatory form of programmed cell death mediated by
gasdermin and requires the caspase-1 activation in inﬂam-
masomes. Various studies have demonstrated pyroptotic
death of macrophages and dendritic cells infected with
intracellular pathogens as one of the key mechanisms for host
survival [318].
4. Conclusion
During infections, there is a constant combat between
pathogens that attempt to establish and maintain an infec-
tion and host immune defense mechanisms to prevent such
establishment. The outcome of this battle is determined by
many factors related to host, pathogen, and the immune
responses. In this review, we highlight host immune defense
mechanisms against microbial infections and the various
anti-immune strategies adopted by the intracellular patho-
gens to thwart this immune defense and establish persistent
infections. New technological advancements in the ﬁeld
of immunology such as genomics, proteomics, RNA
sequencing, and imaging have allowed track of intracellular
persistent infections and the associated cellular changes.
Combining all these robust immunological techniques with
animal models of infectious diseases, including transgenic
and humanized animal models, provides detailed informa-
tion of chemical, epigenetic, and cellular interactions that
occur during persistent infections. Although recent progress
has brought us closer to understanding the mechanisms of
pathogen persistence and counteractive host immunity, a
lot more is still to be explored to completely translate the
host-pathogen interactions during persistent intracellular
infections. An interdisciplinary approach will be critical to
bridging the knowledge gaps in infection dynamics during
persistent infections. With the global presence of emerging
and reemerging infectious diseases and classical infections
continuously present, an improved understanding of this
knowledge is crucial for developing improved disease
diagnostics, interventional strategies, or novel vaccines.
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